Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial of PLX-PAD in Japanese patients with critical limb ischemia

Trial Profile

A pivotal trial of PLX-PAD in Japanese patients with critical limb ischemia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Chronic limb-threatening ischemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Pluri
  • Most Recent Events

    • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
    • 12 Aug 2016 New trial record
    • 02 Aug 2016 According to a Pluristem Therapeutics media release, the company reached an agreement with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the protocol of this trial via Japan's accelerated regulatory pathway for regenerative medicine.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top